Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

By GlobeNewswire Published on June 22, 2025, 18:00 IST Data presented simultaneously at the American Diabetes Association's ® 85 th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions 1
85 Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks 1 *
The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112
Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM .
'In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2,' said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. 'These results reinforce our confidence in CagriSema, and we continue to study the potential of this combination through the REDEFINE trials.'
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group,10.2% reached that threshold at 68 weeks.1
Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body weight reduction of ≥25%.* Additionally, 23.1% lost ≥30% of their body weight.1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction and 19.3% achieved ≥30% body-weight reduction.1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.1
'In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions,' said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. 'Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement.'
Safety data generated in the REDEFINE 1 and 2 trials were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and were mostly transient and mild-to-moderate in severity.1
Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM .3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by > 5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3
The REDEFINE clinical programme will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand; this estimand estimates what the effect would be if all participants adhered to treatment
** Based on the treatment policy estimand: treatment effect regardless of treatment adherence
About CagriSema
CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg.
About the REDEFINE clinical trial programme
REDEFINE is a phase 3 clinical development programme with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo- and controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.
Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2.
About obesity
Obesity is a serious chronic, progressive, and complex disease that requires long-term management.4–6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube .
Contacts for further information
References: Garvey WT, Blüher MD, Contreras CKO, et al. CagriSema in Adults with Overweight or Obesity. New England Journal of Medicine 2025. doi: 10.1056/NEJMoa2502081 ClinicalTrials.gov. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: https://clinicaltrials.gov/study/NCT07011667. Davies MJ, Harpreet S, Bajaj MD, et al. CagriSema in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine 2025. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity . 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev . 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract . 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.html. World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.
Attachment
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

42 minutes ago

• Yahoo

Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing"

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San Francisco-based online health company sold "illegitimate, knockoff versions of Wegovy that put patient safety at risk." Novo Nordisk's move to dissolve the partnership came less than two months after the companies said they were entering a "long-term collaboration" to make obesity treatment more accessible. Shares of Hims & Hers plunged more than $20, or roughly 31%, to $44.10 following Novo Nordisk's announcement. Hims & Hers did not immediately respond to a request for comment. Novo Nordisk said it began selling Wegovy via telehealth companies, including Hims & Hers, after a nationwide shortage of the drug. In offering the drug through more retailers, Novo Nordisk said it wanted to shift patients from using "knock-off, compounded versions" of Wegovy to the Food and Drug Administration-approved semaglutide drug. "After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," a Novo Nordisk spokesperson told CBS MoneyWatch. "This is unacceptable, and that is why we have decided to end the collaboration." The FDA approved Wegovy for adults with obesity in March 2024, adding it to an expanding market of weight-loss drugs that include Ozempic and Mounjaro. Demand for GLP-1 drugs, which are used to treat diabetes and weight loss, has surged in recent years, with one in eight U.S. adults saying they've used the treatments, according to health research publisher KFF. In its release, Novo Nordisk said a company investigation showed that the ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China and that a large share of the drugs were never inspected by the FDA. "U.S. patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," Novo Nordisk said. Novo Nordisk will continue to sell Wegovy on other telehealth platforms that "share our commitment to patient safety," said Dave Moore, executive vice president at Novo Nordisk, in the company's statement. Among the telehealth companies Novo Nordisk partners with are LifeMD and Ro. Kidney dialysis industry accused of maximizing profits over patients Pentagon officials reveal new details about U.S. strikes on Iran's nuclear sites Netanyahu reacts to U.S. strikes on Iranian nuclear sites

Yahoo

an hour ago

• Yahoo

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints

U.S.-listed shares of Novo Nordisk fell more than 5% Monday after the Ozempic and Wegovy maker released results for its newest weight-loss treatment. In a pair of trials, patients lost an average of 22.7% and 15.7% of their body weight over a 68-week period. Separately Monday, Novo Nordisk also said it was ending its partnership with Hims & Hers Health, accusing the digital pharmacy of "illegal mass compounding and deceptive marketing."Novo Nordisk's (NVO) U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the results of a Phase 3 trial for a new weight-loss treatment. The maker of Ozempic and Wegovy said that after a 68-week trial, obese and overweight patients who took CagriSema and followed a treatment plan lost an average of 22.7% of their body weight compared to 2.3% for those in the placebo group. About 40% of the group lost at least 25% of their body weight during the trial, and nearly a quarter lost 30% or more. Just 6% of the trial group stopped taking the drug, mainly due to gastrointestinal issues like nausea and constipation. Novo Nordisk also published results from a second trial Monday, evaluating the drug's effectiveness among overweight or obese patients with type 2 diabetes. At 68 weeks, the average weight loss was about 15.7% of a patient's body weight, and the company said the second trial had similar safety results as the first. Previous trial results for the drug weighed on Novo Nordisk's shares, as CagriSema has yet to achieve the average weight loss of 25% that the company has reportedly hoped for. Shares have also been pressured by trials showing that rival Eli Lilly's (LLY) Mounjaro and Zepbound, along with its drugs in development, are more effective at causing weight loss than Ozempic and Wegovy. U.S.-listed shares of Novo Nordisk are down 20% since the start of 2025 and have lost half their value over the past 12 months. Separately, Novo Nordisk said it has ended its partnership with digital pharmacy Hims & Hers Health (HIMS), and will no longer allow the company to prescribe Wegovy. The companies announced the collaboration in April, but on Monday Novo Nordisk accused Hims of "illegal mass compounding and deceptive marketing." Hims & Hers shares plummeted nearly 30% in recent trading. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CBS News

an hour ago

• CBS News

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San Francisco-based online health company sold "illegitimate, knockoff versions of Wegovy that put patient safety at risk." Novo Nordisk's move to dissolve the partnership came less than two months after the companies said they were entering a "long-term collaboration" to make obesity treatment more accessible. Shares of Hims & Hers plunged more than $20, or roughly 31%, to $44.10 following Novo Nordisk's announcement. Hims & Hers did not immediately respond to a request for comment. Novo Nordisk said it began selling Wegovy via telehealth companies, including Hims & Hers, after a nationwide shortage of the drug. In offering the drug through more retailers, Novo Nordisk said it wanted to shift patients from using "knock-off, compounded versions" of Wegovy to the Food and Drug Administration-approved semaglutide drug. "After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," a Novo Nordisk spokesperson told CBS MoneyWatch. "This is unacceptable, and that is why we have decided to end the collaboration." The FDA approved Wegovy for adults with obesity in March 2024, adding it to an expanding market of weight-loss drugs that include Ozempic and Mounjaro. Demand for GLP-1 drugs, which are used to treat diabetes and weight loss, has surged in recent years, with one in eight U.S. adults saying they've used the treatments, according to health research publisher KFF. In its release, Novo Nordisk said a company investigation showed that the ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China and that a large share of the drugs were never inspected by the FDA. "U.S. patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," Novo Nordisk said. Novo Nordisk will continue to sell Wegovy on other telehealth platforms that "share our commitment to patient safety," said Dave Moore, executive vice president at Novo Nordisk, in the company's statement. Among the telehealth companies Novo Nordisk partners with are LifeMD and Ro.